Passage Bio to Participate in Upcoming Investor Conferences
February 27 2024 - 7:00AM
Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage
genetic medicines company focused on improving the lives of
patients with neurodegenerative diseases, today announced that
management will participate in the following upcoming investor
conferences:
TD Cowen 44th Annual Health Care
ConferenceFormat: Management will participate in a panel
and investor meetingsDate: Tuesday, March 5, 2024Time: 10:30 a.m.
ET Location: Boston, MA
Leerink Partners Global Biopharma Conference
Format: Management will participate in investor meetingsDate:
Wednesday, March 13, 2024Location: Miami, FL
A live webcast of the panel discussion will be available on the
Investors & Media section of Passage Bio’s website at
investors.passagebio.com. A replay of the panel will be available
for 30 days following the event.
About Passage Bio
Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines
company on a mission to improve the lives of patients with
neurodegenerative diseases. Our primary focus is the development
and advancement of cutting-edge, one-time therapies designed to
target the underlying pathology of these conditions. Passage Bio’s
lead product candidate, PBFT02, seeks to treat neurodegenerative
conditions, including frontotemporal dementia, by elevating
progranulin levels to restore lysosomal function and slow disease
progression.
To learn more about Passage Bio and our steadfast commitment to
protecting patients and families against loss in neurodegenerative
conditions, please visit: www.passagebio.com.
For further information, please contact:
Investors:Stuart HendersonPassage
Bio267.866.0114shenderson@passagebio.com
Passage Bio Media:Mike BeyerSam Brown Inc. Healthcare
Communications312.961.2502mikebeyer@sambrown.com
Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From Jul 2024 to Aug 2024
Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From Aug 2023 to Aug 2024